Banque Cantonale Vaudoise Alaunos Therapeutics, Inc. Transaction History

Banque Cantonale Vaudoise

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 17, 2022	SELL	$1.04 - $322.5 $178 - $55,470	-172 Reduced 2.05%	8,211 $14,000
Q2 2022 Aug 02, 2022	BUY	$0.41 - $1.24 $63 - $193	156 Added 1.9%	8,383 $10,000
Q1 2022 May 09, 2022	SELL	$0.62 - $1.17 $9,043 - $17,065	-14,586 Reduced 63.94%	8,227 $5,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $1,862 - $3,230	-1,709 Reduced 6.97%	22,813 $25,000
Q3 2021 Oct 29, 2021	SELL	$1.44 - $2.73 $1,193 - $2,263	-829 Reduced 3.27%	24,522 $45,000
Q1 2021 May 11, 2021	SELL	$2.82 - $5.6 $1,429 - $2,839	-507 Reduced 1.96%	25,351 $91,000
Q4 2020 Feb 05, 2021	SELL	$2.09 - $3.09 $1,285 - $1,900	-615 Reduced 2.32%	25,858 $65,000
Q3 2020 Oct 30, 2020	BUY	$2.39 - $3.43 $207 - $298	87 Added 0.33%	26,473 $66,000
Q2 2020 Jul 22, 2020	SELL	$2.2 - $3.71 $1,863 - $3,142	-847 Reduced 3.11%	26,386 $87,000
Q1 2020 May 14, 2020	SELL	$1.9 - $4.98 $1,069 - $2,803	-563 Reduced 2.03%	27,233 $67,000
Q4 2019 Feb 10, 2020	BUY	$3.95 - $5.35 $109,794 - $148,708	27,796 New	27,796 $131,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

Stay updated on Banque Cantonale Vaudoise with notifications on news.